NCT06126393Not yet recruiting
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
Study on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer Using a Model Constructed by Magnetic Resonance Imaging Radiomics Combined With Pathomics
Source: ClinicalTrials.gov · Last updated 15 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance. However, due to its high cost and complicated process, it is difficult to be widely used in clinical practice. Based on the artificial intelligence method, this study fused the characteristics of MRI radiomics and pathomics, combined with the clinical pathological information, built a model to predict the molecular typing and prognosis, analyzed the biological characteristics of endometrial cancer from the multi-scale level, guided the personalized and precise diagnosis and treatment, in order to improve the prognosis of patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 6 Nov 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Fujian Cancer Hospital
- Diseases
- Endometrial cancer
- NCT number
- NCT06126393
What you commit to
- Study type: Observational
- Planned participants: 350
- From 1 Jan 2024 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- • The image quality is poor or the tumor is too small due to serious graphic artifact and degeneration, and the ROI cannot be accurately delineated;
- Patients who received any antitumor therapy before surgery;
- Diagnostic endometrial biopsy before MRI
Who the study is looking for
- •Pathologically confirmed as endometrial malignant tumor with complete pathological H＆E stained sections;
- Age ≥ 18 years and ≤ 80 years;
- No other malignant cancers was found;
- The complete immunohistochemical and second-generation sequencing results can be used for the molecular typing of ProMisE;
- Magnetic resonance examination was performed within 2 weeks before treatment, and there was at least one measurable lesion according to RECIST 1.1 Criteria.
Age in the registry: 18 years to 80 years · Sex: Female
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.